TY - JOUR
T1 - Allogeneic stem cell transplantation in patients with mantle cell lymphoma
T2 - results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi
AU - Arcari, Annalisa
AU - Morello, Lucia
AU - Vallisa, Daniele
AU - Marcheselli, Luigi
AU - Tecchio, Cristina
AU - Quaglia, Francesca Maria
AU - Tisi, Maria Chiara
AU - Zilioli, Vittorio Ruggero
AU - Di Rocco, Alice
AU - Perrone, Tommasina
AU - Gini, Guido
AU - Dogliotti, Irene
AU - Bianchetti, Nicola
AU - Bozzoli, Valentina
AU - De Philippis, Chiara
AU - Alvarez De Celis, Maria Isabel
AU - Chiappella, Annalisa
AU - Fabbri, Alberto
AU - Pelosini, Matteo
AU - Merli, Michele
AU - Molinari, Anna Lia
AU - Sciarra, Roberta
AU - Volpetti, Stefano
AU - Hohaus, Stefan
AU - Nassi, Luca
AU - Visco, Carlo
PY - 2021/12
Y1 - 2021/12
N2 - The role of allogeneic stem cell transplantation (allo-SCT) in mantle cell lymphoma (MCL) is uncertain, even more in the era of bruton's tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cells. We retrospectively analyzed 55 patients who underwent allo-SCT for MCL relapsed or refractory (r/r) after rituximab and high-dose cytarabine within the MANTLE-FIRST project. With a median follow-up of 3.7 years, non-relapse mortality (NRM), progression-free survival, and overall survival were 23%, 53%, and 56%, respectively. NRM was significantly higher in the case of acute graft-versus-host disease, > 2 prior lines of therapy, age > 60 years. The outcome was similar for patients with early (≤24 months) and late progression of disease. The use of BTKi as a bridge to allo-SCT did not increase the toxicity and allowed a good control of disease. Our real-life experience confirms that allo-SCT still represents an option in MCL patients, especially if young and early-relapsed.
AB - The role of allogeneic stem cell transplantation (allo-SCT) in mantle cell lymphoma (MCL) is uncertain, even more in the era of bruton's tyrosine kinase inhibitors (BTKi) and chimeric antigen receptor T-cells. We retrospectively analyzed 55 patients who underwent allo-SCT for MCL relapsed or refractory (r/r) after rituximab and high-dose cytarabine within the MANTLE-FIRST project. With a median follow-up of 3.7 years, non-relapse mortality (NRM), progression-free survival, and overall survival were 23%, 53%, and 56%, respectively. NRM was significantly higher in the case of acute graft-versus-host disease, > 2 prior lines of therapy, age > 60 years. The outcome was similar for patients with early (≤24 months) and late progression of disease. The use of BTKi as a bridge to allo-SCT did not increase the toxicity and allowed a good control of disease. Our real-life experience confirms that allo-SCT still represents an option in MCL patients, especially if young and early-relapsed.
U2 - 10.1080/10428194.2021.1961238
DO - 10.1080/10428194.2021.1961238
M3 - Article
C2 - 34625013
SN - 1042-8194
VL - 62
SP - 3474
EP - 3483
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -